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Abstract: Childhood chronic arthritis of unknown etiology is known collectively as juvenile idiopathic arthritis
(JIA) and consists of heterogeneous subtypes with unique clinical patterns of disease. JIA is the commonest
rheumatic disease in children and may still result in significant disability, with joint deformity, growth impair-
ment, and persistence of active arthritis into adulthood. Basic research is rather focused on rheumatoid arthri-
tis, and this lead to small number of publications considering JIA. In this study we examine, by flow cytometry,
the expression of dendritic cells (DCs) in the peripheral blood and synovial fluid of children with active JIA in
a group of 220 patients. We reveal a significant decrease in the percentage of immature DCs in the blood of
patients compared to control children. Surprisingly, we found higher percentages of mature circulating den-
dritic cells. Both populations of DCs, immature and mature, were accumulated in patients’ synovial fluid. We
also confirmed the presence of CD206+/CD209+ in JIA samples, which can represent a population of mac-
rophages with dendritic cells morphology. Our results support the thesis that dendritic cells are crucial in the
induction and maintenance of autoimmune response and local inflammation during juvenile idiopathic arthri-
tis. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 188–199)
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Introduction
A combination of genetic and environmental factors
predisposes to the development of autoimmune re-
action. Stimulation of autoreactive lymphocytes by
professional antigen presenting cells (APCs) is cru-
cial for the beginning of a vicious circle of reactions
leading to the destruction of tissues and organs. Ba-
sic experiments and animal models show that den-
dritic cells’ (DCs) immunostimulatory functions and
dysregulation of tolerogenic properties play a pivotal
role in the pathogenesis of arthritis [1, 2].
Dendritic cells comprise a complex network of
multifarious antigen presenting cells that are impor-
tant not only to the orchestration of active immune
response, but also to the maintenance of both cen-
tral and peripheral tolerance. It is well-known that
DCs do not represent a homogenous cell population,
but are a mixture of at least two populations: mye-
loid and lymphoid dendritic cells, which vary in tis-
sue distribution, morphology, function, and immu-
nophenotype [3, 4]. Immature myeloid dendritic cells
(mDCs) are of monocytoid morphology and express
myeloid markers such as: CD13, CD33 and CD11c
antigen. Myeloid immature dendritic cells also ex-
press characteristic antigens such as BDCA-1 (CD1c)
or BDCA-3 [4]. Plasmocytoid DCs (pDCs) are CD4
and CD123 positive, CD11c negative, and express
neither myeloid lineage markers such as CD13 or
CD33, nor Fc receptors. These cells also express rela-
tively lower levels of HLA-DR and HLA-DQ. Circu-
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lating plasmacytoid dendritic cells express character-
istic antigen BDCA-2 (CD303) or BDCA-4 (CD304)
[4].
The expression of surface molecules on DCs is
dynamic and changes according to tissue localization
and maturation state. Most of the immature DCs are
characterized by expression of molecules associated
with antigen uptake. On the other hand, mature DCs
lose their capacity for antigen engulfment, and ac-
quire molecules necessary for stimulation of T lym-
phocytes e.g. CD83, CD80, and CD86 [3].
The role of dendritic cells in the pathogenesis and
the clinical course of disease, as well as in the thera-
py of rheumatoid arthritis has been intensively inves-
tigated and was reviewed by Lebre and Ruttela [1, 2,
5]. Unfortunately, as yet, insufficient work has focused
on the function and dysfunction of DCs in juvenile
idiopathic arthritis (JIA).
According to the International League of Associa-
tions for Rheumatology, the term ‘juvenile idiopathic
arthritis’ comprises a heterogeneous group of chronic
disease subtypes that are characterized by arthritis
beginning before the age of 16 with symptoms per-
sisting for more than six weeks [6, 7]. The etiology of
JIA is still poorly understood, despite it being the
commonest autoimmune disease in children. Al-
though new therapeutic approaches have been iden-
tified, many children still suffer severe long-term disa-
bility. According to the type of onset of disease, juve-
nile idiopathic arthritis has been classified into ho-
mogenous subtypes for a better understanding of its
epidemiology and pathogenesis, as well as for im-
provement in quality of multicenter clinical studies
[6, 7]. Oligoarthritis and polyarthritis are the preva-
lent subtypes of JIA and comprise most cases. Next
most common are other categories of JIA like: en-
thesitis-related arthritis, psoriatic arthritis, systemic
arthritis and undifferentiated arthritis [7]. A combi-
nation of environmental and immunologic factors
(e.g. infections) and a certain genetic (e.g. specific
HLA allels) susceptibility may contribute to this dis-
order. Since there is no pathognomic finding for this
group of arthritis, diagnosis is based on the combined
evaluation of anamnesis, clinical presentation and,
to some extent, laboratory abnormalities.
The aim of our study was to examine the ex-
pression of different DCs’ markers in the periphe-
ral blood and inflammatory synovial fluid during
JIA exacerbation and to compare these findings to
the same populations of DCs in the blood of healthy
children and non-inflammatory synovial fluid. To
the best of our knowledge, this is the first large
cohort study describing immature and mature den-
dritic cells in the blood and synovial fluid of pa-
tients with JIA.
Material and methods
Patients and controls
220 patients who fulfilled ILAR criteria for JIA (Ed-
monton, 2001) and were treated in the Department
of Pediatrics, Lung Diseases and Rheumatology,
Medical University of Lublin between 2001 and 2009
were included in the study. Of these, all provided
peripheral blood (PB) samples and 52 (none with
systemic JIA) also provided synovial fluid (SF) sam-
ples. Of the 220 children who suffered from JIA,
55% were diagnosed with oligoarticular onset, 25%
polyarticular onset, 5% systemic onset and 15% en-
thesitis-related arthritis. The age of the patients
ranged from one to 19 years (mean 11.26 ± 4.6) and
68.1% of them were girls. All samples were collec-
ted during the acute phase of the disease. Peripher-
al blood was taken during blood collection for diag-
nostic procedures, and synovial fluid was collected
during therapeutic puncture of the knee joint. Fifty
control children provided PB samples during exami-
nation before minor surgery and were enrolled into
the control group after exclusion of any disease ex-
cept minor injury. In addition, we examined sam-
ples of post-traumatic non-inflammatory synovial
fluid from 20 adult patients subjected to orthopedic
surgery after injury  of knees’ ligaments. The study
was approved by the Bioethics Committee of the
Medical University of Lublin, and all statutory
guardians of juvenile patients gave their informed
consent for the study. Those aged over 16 gave their
own informed consent.
Isolation of the peripheral blood and synovial fluid
mononuclear cells
Peripheral blood and synovial fluid were collected in
sterile heparinized tubes. Mononuclear cells were
separated by gradient centrifugation over Gradisol-L
(Aqua Medica, Poland) and washed twice in PBS
(phosphate buffered saline) (PAA, Austria) without
Ca2+ and Mg2+, containing 0.5% BSA (bovine serum
albumin) (Sigma, Germany) and 2 mM EDTA (Sig-
ma-Aldrich, Germany).
Immunophenotyping of the cells
The cell surface antigens in each case were deter-
mined on fresh cells at the time of sample submis-
sion. The following directly conjugated monoclonal
antibodies were used: mouse anti-human BDCA-1
(CD1c)-FITC (Miltenyi-Biotec, Germany), BDCA-2
(CD303)-FITC (Miltenyi-Biotec, Germany), CD123-
-PE (Becton Dickinson, USA), CD19-PE-Cy5 (BD
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Pharmingen, USA). For the estimation of DCs mat-
uration and function marker, we used the following
combinations of antibodies: anti-CD83 FITC/anti-
-CD1a PE/anti-HLA-DR PE-Cy5, anti-CD80 FITC/
/anti-CD86 PE/anti-HLA-DR PE-Cy5 and CD209
FITC/CD206 PE/anti-HLA-DR PE-Cy5, all of them
from BD Pharmingen, USA. Immunofluorescent
staining was prepared according to manufacturers’
protocols. Class matched isotype control was used to
establish unspecific binding. Cells were collected us-
ing a three-color FACSCalibur flow cytometer
equipped with 488-nm argon laser (Becton Dickinson,
USA) and analyzed with CellQuest and FlowJo 7.5
software. We collected 300,000 total events. Cell de-
bris and dead cells were excluded from the analysis
based on scatter signals and PI staining. The mononu-
clear cell analysis region was analyzed for CD1c and
CD 19 staining. CD1c+ B cells were excluded from
CD1c+ blood dendritic cells by counter-staining for
CD19. CD1c+/CD19– cells were counted as immature
myeloid DCs. Next, the mononuclear cell analysis re-
gion was analyzed for CD303 and CD123 antigens.
CD303+/CD123+ cells are counted as immature plas-
macytoid DCs. Representative sample analysis is shown
in Figures 1 and 2. Results are expressed as percen-
tage of the cells in mononuclear cells gate.
Statistical analysis
Kruskal Wallis ANOVA, U-Mann–Whitney and Wil-
coxon non-parametric tests and Statistica 9 PL soft-
ware were applied to statistical analysis. All results
are showed as medians and interquartile range (IQR).
Results
CD1c+ myeloid and CD303+ plasmacytoid
dendritic cells in peripheral blood and
inflammatory synovial fluid in children with JIA
We evaluated the percentages of myeloid and plasma-
cytoid subpopulation of DCs as well as the relation
between these cells and the total percentage of imma-
ture dendritic cells. It is well known that myeloid and
lymphoid dendritic cells differ in cytokines profile and
function, so we believe that balance between these two
populations is one of the crucial points in immune re-
sponse. In children with JIA, we found a statistically
significant (p = 0.000000001) higher percentage of
immature myeloid DCs in SF (3.47%; 3.55) than in
the peripheral blood (0.43%; 0.31) (Figure 3). The
percentage of immature plasmacytoid dendritic cells
was also significantly (p = 0.00000001) higher in in-
flammatory SF (0.84%; 1.56) than in PB (0.35%; 0.37)
(Figure 3). The increased percentages in SF of both
subpopulations of immature DCs result in a signifi-
cantly (p = 0.000000001) higher total percentage of
immature DCs in SF (5.13%; 4.08) than in PB (0.79%;
0.61) (Figure 3). We also concluded that in inflamma-
tory SF of children with JIA, myeloid immature den-
dritic cells are in the majority. Myeloid/plasmacytoid
DCs ratio in SF was 4.58; 6.95 and it was significantly
(p = 0.00003) higher than in PB (1.2; 1.30).
Differences in immature DCs percentages
between JIA subtypes
Using a Kruskal Wallis test we found that groups
representing diverse categories of JIA significant-
ly (H = 8.36, p = 0.04) differ in percentages of
CD1c+ dendritic cells (Figure 4). We concluded
that patients with systemic JIA have the lowest per-
centages of myeloid DCs 0.16% (0.26) and paired
U Mann–Whitney tests showed significant differe-
nces when compared to other types of JIA: poly-
articular (p = 0.01), oligoarticular (0.004) and en-
thesitis-related arthritis (p = 0.01) onset. We did
not find any significant differences in other exam-
ined parameters. However, the percentage of pDCs
in systemic JIA was about twice lower that in the
other subtypes of JIA, and almost a four times that
in the control group. Detailed results are summa-
rized in Table 1.
Differences in immature DCs percentages between
JIA patients and control groups
We found that children with JIA have significantly
lower percentages of circulating myeloid and plas-
macytoid DCs (p = 0.0003 and p = 0.0002 respec-
tively). Decreasing percentages of both DCs subpop-
ulations lead to significantly (p = 0.000003) lower
total percentage of DCs. When comparing inflam-
matory synovial fluid to post-traumatic synovial flu-
id, we found significantly higher percentages of mye-
loid and plasmacytoid DCs (p = 0.000000003 and
p = 0.0000009 respectively) as well as total percent-
age of DCs (p = 0.000000005) in children with JIA.
Differences were also significant for each examined
subtype of juvenile idiopathic arthritis. We did not
find significant differences in myeloid/plasmacytoid ra-
tio, either in blood or synovial fluid. Percentages of
analyzed cells populations are summarized in Table 1.
Differences in DCs expressing CD83 and CD1a
in peripheral blood and synovial fluid
of children with JIA
We found higher percentages of CD83+/HLA–DR+
(p = 0.0002) and CD1a+/HLA–DR+ (p = 0.003) cells
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Figure 1. Cytometric analysis of CD1c+/CD19– and CD303+/CD123+ dendritic cells in peripheral blood and synovial
fluid of representative patient with JIA. A. Gating of PBMCs — R1; B. Gating of myeloid DCs — R2; C. Gating of
plasmacytoid DCs — R2
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Figure 2. Dot-plots representing cytometric analysis of representative patient with JIA. A. Gating of CD83 and CD1a
positive cells; B. Gating of CD80 CD86 positive cells; C. Gating of CD209 and CD206 positive cells
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in SF than in PB (Figure 3). When we analyzed co-
expression of CD83 and CD1a, we concluded that
all populations: CD83+/CD1a–/HLA–DR+, CD83+/
/CD1a+/HLA–DR+, CD83–/CD1a+/HLA–DR+, were
significantly accumulated in synovial fluid p = 0.0001,
p = 0.003, p = 0.002 respectively (Figure 3). We did
not find any statistically significant differences in
CD83 and CD1a expressing cells of children with dif-
ferent disease onsets. Comparison between JIA pa-
tients and healthy children revealed that percentag-
es of CD83+/HLA–DR+ and CD1a/HLA–DR+ cells
were higher in the PB of children with juvenile ar-
thritis, p = 0.03 and p = 0.02 respectively (Table 1).
We also concluded that CD83/CD1a double positive
and CD83–/CD1a+/HLA–DR+ populations were sig-
nificantly (p = 0.02 and p = 0.04 respectively) ac-
cumulated in the blood of JIA patients, but not
CD83+/CD1a–/HLA–DR+ cells. In inflammatory SF
we found a significantly (p = 0.03) higher total per-
centage of CD83+/HLA–DR+, but not CD1a+/HLA–
–DR+ cells when compared to post-traumatic SF. Un-
like with blood, in JIA SF we found a significantly
(p = 0.04) higher percentage of C83+/CD1a–/HLA–
–DR+ cells, but not CD83+/CD1a+/HLA–DR+ cells.
CD83–/CD1a+/HLA–DR+ cells were also significantly
higher in the SF of children with JIA compared to
controls. Percentages of cells bearing particular im-
munophenotypes are shown in Table 1.
CD80 and CD86 expressing cells in the PB
and SF of JIA patients
Our results showed that percentages of CD80+/HLA–
–DR+ and CD86+/HLA–DR+ were significantly (p =
= 0.01 and p = 0.005 respectively) higher in the SF
than in the PB of JIA children (Figure 3). Analysis of
co-expression of CD80 and CD86 revealed that num-
bers of double positive CD80 and CD86, as well as
CD80–/CD86+/HLA–DR+ cells, were significantly (p =
= 0.01 and p = 0.04) higher in synovial fluid (Figure 3).
We did not confirm a difference in the CD80+/CD86–/
/HLA–DR+ population. We also did not observe any
significant differences between JIA onset subtypes.
Figure 4. Percentage of circulating myeloid dendritic cells
was lowest in children with systematic JIA. ANOVA
statistical analysis of different subtypes of JIA revealed
significant difference (H = 8.36; p = 0.04). This differen-
ce was confirmed by paired analysis and percentage of
circulating mDCs was lower than in control group
(p = 0.00004), oligoarthritis (p = 0.004), polyarthritis
(p = 0.01), enthesitis-related arthritis (p = 0.01)
Figure 3. Percentages (shown as medians) of cell populations expressing different DCs markers in peripheral blood
and synovial fluid of children with JIA. All differences were statistically significant, except comparison of CD80–/
/CD86+/HLA–DR+ cells
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Table 1. Percentages of the cells of particular immunophenotypes in mononuclear cells gate. Results are shown as
median followed by IQR. Significant differences between groups are described in the ‘Results’ section of the text
   Immunophenotype Percentage of cells among PBMCs
Peripheral blood
JIA n = 220 Systemic Polyarthritis Oligoarthritis Enthesitis-
arthritis n = 11 n = 55 n = 121 -related arthritis
n = 33
CD1c+/CD19– mDCs 0.43 (0.31) 0.16 (0.26) 0.43 (0.31) 0.43 (0.30) 0.43 (0.25)
CD303+/CD123+ pDCs 0.35 (0.37) 0.14 (0.40) 0.34 (0.42) 0.38 (0.34) 0.30 (0.40)
Total immature DCs 0.79 (0.61) 0.36 (0.86) 0.79 (0.77) 0.83 (0.55) 0.82 (0.66)
mDCs/pDCs Ratio 1.20 (1.30) 1.17 (2.70) 1.28 (1.58) 1.18 (1.22) 1.32 (1.30)
CD83+/CD1a–/HLA–DR+ 0.23 (0.23) 0.22 (0.15) 0.24 (0.27) 0.21 (0.25) 0.23 (0.20)
CD83+/CD1a+/HLA–DR+ 0.27 (0.41) 0.06 (0.26) 0.35 (0.49) 0.32 (0.42) 0.14 (0.27)
CD83–/CD1a+/HLA–DR+ 0.11 (0.20) 0.05 (0.15) 0.17 (0.14) 0.11 (0.20) 0.07 (0.20)
CD83+/HLA–DR+ Total 0.56 (0.65) 0.28 (0.39) 0.64 (0.69) 0.62 (0.65) 0.35 (0.27)
CD1a+/HLA–DR+  Total 0.43 (0.63) 0.11 (0.41) 0.52 (0.55) 0.40 (0.67) 0.34 (0.39)
CD80+/CD86–/HLA–DR+ 1.83 (2.08) 1.25 (1.50) 1.63 (2.09) 1.95 (2.13) 2.22 (1.75)
CD80+/CD86+/HLA–DR+ 3.07 (6.16) 5.09 (7.74) 2.59 (4.86) 2.63 (5.21) 5.89 (9.13)
CD80–/CD86+/HLA–DR+ 8.59 (8.89) 10.07 (12.30) 8.96 (7.90) 8.14 (8.71) 9.14 (8.05)
CD80+/HLA–DR+  Total 5.26 (7.45) 6.57 (11.67) 4.22 (6.16) 5.28 (6.75) 8.78 (11.12)
CD86+/HLA–DR+ Total 13.90 (9.75) 15.38 (13.74) 13.57 (11.96) 13.86 (10.28) 15.97 (7.04)
CD206+/HLA–DR+ Total 0.64 (0.51) 0.44 (0.76) 0.43 (0.41) 66 (0.56) 0.57 (0.10)
CD209+/HLA–DR+  Total 0.68 (0.39) 0.47 (0.51) 0.84 (0.92) 0.68 (0.39) 0.69 (0.51)
CD206+ among 47.00 (29.00) 43.00 (58.00) 31.00 (26.00) 42.00 (29.00) 58.00 (18.00)
 CD209+–/HLA–DR+
Comparison between the PB of children with JIA and
the control group showed significant difference only in
percentage of CD80–/CD86+/HLA–DR+ cells, which
were in lower numbers in the blood samples of JIA pa-
tients. When we compared inflammatory SF to post-
traumatic SF, we concluded that percentages of CD80+/
/HLA–DR+ cells and CD86+/HLA–DR+ were signifi-
cantly (p = 0.00002 and p = 0.009) higher in inflamed
joints. These differences were made by CD80+/CD86–/
/HLA–DR+ (p = 0.00003) and CD80+/CD86+/HLA–
–DR+ (p = 0.0001), and there was no significant diffe-
rence in CD80–/CD86+/HLA–DR+ population. Per-
centages of each cells population are set out in Table 1.
Analysis of CD206 positive cells in blood
and synovial fluid
We found a significantly (p = 0.001) higher percen-
tage of CD206+/HLA–DR+ cells in SF than in PB of
children with JIA (Figure 3); also, expression of
CD206 shown as MFI (Mean Fluorescence Intensi-
ty) was higher (p = 0.005) on  mononuclear cells from
SF than in PB. There were no differences in the per-
centage of positive cells or expression of CD206 bet-
ween different types of JIA onset. Comparison bet-
ween JIA patients and controls revealed a higher
(p = 0.04) percentage of CD206+/HLA–DR+ cells
in the blood of children with arthritis. We did not
observe any further differences in CD206+ cells. Re-
sults are summarized in Table 1.
Analysis of CD209 positive cells in blood
and synovial fluid
We found a significantly (p = 0.04) higher percen-
tage of CD209+/HLA–DR+ cells in SF than in PB
(Figure 3), also expression of CD209 on SF mononu-
clear leukocytes was higher (p = 0.005). Patients with
different types of JIA onset did not differ in percent-
age of CD209+ cells and expression of this molecule.
We noticed higher percentages of CD209+/HLA–
–DR+ cells in both blood (p = 0.03) and synovial fluid
(p = 0.02) compared to controls. MFI of CD209 did
not differ significantly between JIA children and con-
trol samples. We also found that the percentage of
CD209+ expressing CD206 was significantly (p = 0.005)
higher in JIA SF than in JIA PB. We did not confirm
any differences in CD209+/CD206+ cells between
patients suffering different subtypes of arthritis and
between patients and reference groups.
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Percentage of cells among PBMCs
Synovial fluid
Control JIA n = 52 Systemic Polyarthritis  Oligoarthritis Enthesitis- Control n = 20
n = 50 arthritis n = 5 n = 40 -related arthritis
n = 0 n = 7
0.55 (0.20) 3.47 (3.55) – 2.77 (2.66) 3.30 (3.56) 4.78 (4.53) 0.17 (0.80)
0.51 (0.28) 0.84 (1.56) – 1.27 (1.34) 0.88 (1.54) 0.32 (0.34) 0.07 (0.24)
1.03 (0.46) 5.13 (4.08) – 4.59 (4.13) 5.18 (3.61) 5.43 (4.89) 0.20 (1.05)
1.06 (1.04) 4.58 (6.95) – 6.52 (7.83) 3.71 (6.30) 9.76 (13.35) 1.49 (13.45)
0.18 (0.21) 0.71 (0.99) – 1.18 (2.16) 0.56 (1.09) 0.90 (0.86) 0.40 (0.34)
0.07 (0.09) 0.45 (1.53) – 0.40 (1.56) 0.46 (1.48) 1.80 (1.88) 1.44 (2.03)
0.06 (0.13) 0.26 (0.63) – 0.26 (0.19) 0.29 (0.74) 0.21 (0.22) 0.09 (0.07)
0.26 (0.37) 1.62 (2.46) – 1.58 (2.60) 1.66 (2.61) 2.70 (2.74) 0.74 (0.57)
0.14 (0.29) 1.21 (2.18) – 0.66 (0.95) 1.16 (2.75) 2.00 (1.67) 0.56 (1.70)
1.25 (2.75) 2.90 (4.09) – 3.44 (4.12) 2.54 (3.07) 5.20 (7.32) 0.06 (0.04)
2.91 (5.49) 10.38 (15.66) – 22.67 (28.60) 10.76 (13.94) 3.52 (20.67) 0.53 (0.25)
13.19 (12.40) 8.80 (18.72) – 5.75 (9.25) 10.68 (18.25) 8.80 (24.35) 12.37 (13.28)
4.52 (7.74) 14.51 (18.65) – 26.11 (31.20) 14.33 (17.93) 10.88 (25.83) 0.57 (0.22)
17.81 (9.11) 24.79 (21.11) – 28.42 (39.44) 24.60 (21.37) 28.33 (24.63) 12.87 (13.48)
0.26 (0.24) 4.92 (6.26) – 0.85 (1.28) 4.42 (6.75) 4.91 (0.31) 3.88 (4.40)
0.25 (0.40) 1.14 (2.09) – 0.78 (1.11) 1.40 (2.22) 0.63 (0.39) 0.51 (0.54)
29.00 (20.00) 76.00 (48.00) – 79.00 (30.54) 75.00 (50.00) 74.00 (8.00) 61.00 (29.00)
HLA-DR positive cells in blood and synovial fluid
The total percentage of HLA–DR positive cells did
not differ between PB and SF of children with JIA.
On the other hand, expression of HLA–DR was sig-
nificantly (p = 0.003) higher in synovial fluid. We
did not found any differences in the percentage of
HLA–DR positive cells between JIA subtypes or JIA
children compared to control groups. Percentages of
each population are shown in Table 1.
Discussion
Dendritic cells are thought to play a pivotal role in
driving the immunopathogenic response essential for
chronic inflammatory arthritis. Multiple studies have
showed accumulation of DCs, at different matura-
tion stages and of different lineage, in synovial fluid
and synovial tissue of patients with rheumatoid ar-
thritis [8–15]. Smolewska et al. described the accu-
mulation of DCs in the synovial fluid of children with
juvenile idiopathic arthritis [16–17]. Since the patho-
genesis of JIA is still unknown, the evaluation of den-
dritic cells distribution in peripheral blood and syno-
vial compartment may be important in understanding
the immunopathogenesis of chronic synovial inflam-
mation and cartilage destruction. Our study shows
for the first time the results of complex evaluation of
dendritic cells of different lineages and maturation
stages in a large cohort of patients with JIA.
Our results showed a significant decrease in cir-
culating CD1c+/CD19– myeloid and CD303+/CD123+
plasmacytoid DCs in children with JIA, compared to
healthy children. Decreased peripheral blood den-
dritic cells percentages most probably reflect DCs
migration and accumulation to the inflamed joints.
This is consistent with our results showing significantly
higher percentages of mDCs as well as pDCs in paired
synovial fluid collected during therapeutic joint punc-
ture. To confirm that greater levels of DCs are chara-
cteristic of inflammatory SF, we checked the presence
of dendritic cells in post-traumatic synovial fluid. We
found that SF from inflamed joints contains signifi-
cantly higher percentages of mDCS and pDCs than
post-traumatic SF. Jongbloed et al. showed similar
results in patients with RA, when they checked abso-
lute count of CD1c+ and CD303+ DCs [14]. Richez
et al. found similar results for CD11c+/HLA–DR+
mDCs and CD123+/HLA–DR+ pDCs enumerated in
blood and synovial fluid of patients with rheumatoid
Table 1. Continued
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arthritis [18]. Cavanagh et al. also described a higher
percentage of myeloid and plasmacytoid DCs in RA
SF, but only PB mDCs, not pDCs, were decreased
when compared to the blood of healthy donors [15].
Kavousanaki et al. found decreased percentages of
CD45+/CD1c+/CD11c+/CD303– myeloid DCs and
CD303+ plasmacytoid DCs in patients with active
rheumatoid arthritis, but not during remission [12].
They also described high number of mDCs ª 15% in
inflammatory SF. On the other hand, surprisingly,
they were not able to detect any CD303+ in SF. Defi-
ciency in circulating mDCs and pDCs, as well as ac-
cumulation of DCs in the synovial compartment in
children with JIA, have been described by Smolew-
ska et al. and their results accord with ours [16]. Jong-
bloed et al. and Smolewska et al. described signifi-
cantly increased mDCs to pDCs ratios in RA and JIA
respectively [14, 16]. These findings are consistent
with our results.
Dendritic cells are thought to be very potent in-
ducers of specific immune response, but they also play
an important role in the maintenance of immune tol-
erance. Immunostimulatory or tolerogenic features
of DCs depend on lineage and maturation stage. We
showed accumulation of both populations CD1c+/
/CD19– and CD303+/CD123+ in inflamed joint envi-
ronment, and these findings prompt us to raise the
question whether DCs in SF are proinflammatory
cells, or represent a cell population which loses regu-
latory potential. Dendritic cells expressing CD1c+ or
CD303+ are either considered as immature or matu-
rating DCs [4]. Lim et al. showed that semi-mature
CD11c+ DCs are immunogenic and, when injected
at a high dose, they accelerated collagen-induced ar-
thritis in mice. Only low doses of these cells showed
anti-arthritic activity [19]. Cavanagh et al. confirmed
that mDCs and pDCs isolated from RA SF efficient-
ly stimulated proliferation and IFN-g and IL-10 pro-
duction by resting normal allogeneic T lymphocytes
[15]. Contradicting the results described above,
Kavousanaki et al. found that plasmacytoid DCs could
be educated within the rheumatoid microenviron-
ment to acquire tolerogenic phenotype [12]. They
showed that matured pDCs from RA patients with
low disease activity, but not from healthy donors, ex-
pressed high levels of indoleamine 2,3-dioxygenase
and promoted differentiation of IL-10 positive T regu-
latory lymphocytes. Using a mouse model of arthri-
tis, Jongbloed et al. showed that selective in vivo de-
pletion of pDCs enhanced T and B cells immune res-
ponse against collagen and severity of articular in-
flammation [20]. Furthermore, immature and mature
myeloid DCs can expand Treg numbers, which are
able to block the maturation of further dendritic cells
[21–23]. Sidhu et al. showed that vaccination with
immature DCs pulsed with type II collagen could sig-
nificantly delay the onset of mouse spontaneous poly-
chondritis [24]. These results open the gates for us-
ing DCs in the therapy of human arthritis.
Systemic juvenile idiopathic arthritis (sJIA) is
a rare, systemic inflammatory disease characterized
by arthritis and systemic features such as spiking fe-
ver, skin rash, hepatosplenomegaly or serositis. Now-
adays, it is clear that abnormalities in the innate im-
munity play a crucial role in the development of sJIA.
Moreover, this subtype of arthritis is strongly associ-
ated with macrophage activation syndrome.
In this present paper, we showed that patients with
sJIA represent the lowest percentages of circulating
CD1c+ myeloid dendritic cells, and this difference
was confirmed in Kruskal–Wallis test and paired
analysis. Unfortunately, we were unable to collect SF
samples from any patients with sJIA. Our results could
support previous work which has revealed that it is
mainly cells of myeloid lineage that participate in the
pathogenesis of sJIA [25]. Contradicting our results,
Macaubas et al. showed a decrease not only in circu-
lating mDCs, but also in pDCs, in patients with ac-
tive sJIA [26].
Human CD83 is a 45-kDa glycoprotein and
a member of the Ig superfamily expressed on mature
dendritic cells [27]. CD1a belongs to the highly con-
served and closely related group of CD1 proteins,
which mediate the presentation of primarily lipid and
glycolipid antigens of self or microbial origin to T cells
[28].
In this study, we checked co-expression of CD83
and CD1a in peripheral blood and synovial fluid of
children with JIA. We found significantly higher per-
centages of  CD83+/CD1a–/HLA–DR+, CD83+/
/CD1a+/HLA–DR+, CD83–/CD1a+/HLA–DR+ in
synovial fluid than in peripheral blood. Previous re-
search has confirmed the presence of cells expres-
sing CD1a or CD83 in the synovial tissue of patients
with arthritis [9, 10, 29, 30]. Smolewska et al. con-
firmed expression of C83 on CD1c positive dendritic
cells in the synovial fluid of JIA patients [17]. The
CD83 molecule could be important not only when
expressed on the cell surface, but also in soluble form.
Hock et al. confirmed a higher concentration of
sCD83 in RA SF than in the synovial fluid of patients
with osteoarthritis [31]. The role of CD1a+ dendritic
cells in cartilage destruction is not restricted to stimu-
lation of immune response; they could actively de-
stroy joint structures. Rivollier et al. showed that in
the arthritis microenvironment, CD1a+/HLA–DR+/
/CD83low/CD80low/CD86low dendritic cells are ca-
pable of turning into active osteoclasts [32]. Lakey et
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al. proved that mature monocytes derived dendritic
cells destroy cartilage collagen through an indirect
mechanism mediated by TNF-a [33]. We also con-
cluded that percentages of dendritic cells expressing
CD1a: CD83+/CD1a+/HLA–DR+ and CD83–/
/CD1a+/HLA–DR+ were higher in the PB of children
with JIA. On the other hand, in synovial fluid we
found higher percentages of CD83+/CD1a–/HLA–
–DR+ and CD83–/CD1a+/HLA–DR+ than in post-
traumatic SF. This finding suggests that inflammato-
ry synovial fluid can induce maturation of DCs and
upregulation of CD83 and loss of CD1a, so in inflam-
matory SF we see relatively small amounts of semi-
mature CD83/CD1a double positive cells. Our group
confirmed that inflammatory synovial fluid is an effi-
cient inducer of monocytes derived dendritic cells
generation and maturation [34]. In agreement with
our results, Saito et al. confirmed the paucity of
CD1a+ expressing cells in the synovial tissue of pa-
tients with osteoarthritis [35]. Our data, supported
by reviewed articles, strengthens the thesis that the
synovial microenvironment during autoimmune ar-
thritis, such as RA and JIA, attracts dendritic cells,
which become mature in inflamed joints. On the ot-
her hand, it has been proved that C-reactive protein
as well as immune complexes inhibit the differentia-
tion, maturation and function of monocytes derived
dendritic cells [36, 37].
CD80 (B7-1) and CD86 (B7-2) are both type 1
transmembrane proteins, which mediate costimula-
tion of T-cell activation and differentiation, and may
therefore affect the course of different human dise-
ases [38, 39]. Our study showed higher total percen-
tages of cells expressing both costimulatory molecules
in SF than in PB of children with JIA. Also, when we
compared blood and synovial fluid of patients to sam-
ples from the control group, we found a decrease of
CD80–/CD86+/HLA–DR in JIA PB and CD80+/
/CD86+/HLA–DR+ as well as CD80+/CD86–/HLA–
–DR+ in JIA SF.
These results indicate that inflammatory SF in-
duces maturation of DCs, because CD86 is constitu-
tively expressed on APCs, unlike CD80, the expres-
sion of which is induced. Using the mouse model of
Streptococcus-induced arthritis, Puliti et al. showed
that lack of CD80 resulted in a lower incidence and
severity of articular lesions, while lack of CD86 led
to worsening of arthritis [38].
CD209 (DC-SIGN) is a C-type lectin expressed
on phagocytic cells such as DCs and macrophages
which is involved in the infectious pathogen recog-
nition and stimulation of innate immune response
[40–42]. CD206 (mannose receptor, also known as
the macrophage mannose receptor) has been shown
to bind and internalize carbohydrate and collagen
ligands and to have a role in myoblast motility and
muscle growth [43]. We confirmed the accumulation
of CD206 or CD209 expressing cells in the synovial
fluid of children with JIA, and also that double posi-
tive cells were found in higher numbers in SF. The
percentage of CD206 positive cells was higher in the
blood of children with JIA, but was no difference in
SF when compared to controls. CD209 were accu-
mulated in PB and SF when compared to the blood
of healthy children or post-traumatic synovial fluid.
Accumulation of CD209+ could confirm mature state
of DCs in inflammatory synovial fluid, but Ochoa et
al. showed that DC-SIGN is expressed on CD206+
macrophages with DCs-like morphology [44]. Addi-
tionally, Dieguez-Gonzales et al. showed in single nu-
cleotide polymorphism a lack of association of CD209
encoding genes with rheumatoid arthritis [41].
In summary, our investigation is the first study
describing dendritic cells population in juvenile idio-
pathic arthritis in which a large cohort of 220 patients
with active JIA was included. Our research compared
inflammatory SF to post-traumatic SF (collected
a short time after injury), unlike other studies of syno-
vial fluid from patients with osteoarthritis. Because
of this difference, we were able to compare SF not
between two inflammatory diseases, but between au-
toimmune inflammation and non-inflammatary exu-
dations. We noticed a significant decrease of CD1c+
myeloid and CD303+ plasmacytoid dendritic cells in
the peripheral blood of children with JIA. This seems
to be due to migration of DCs to inflamed joints,
where they mature and stimulate autoimmune re-
sponse.
Dendritic cells could be the main population of
leukocytes responsible for induction and prolonga-
tion of local inflammatory response. In synovial flu-
id, we also confirmed the presence of CD206/CD209
double positive cells which could represent a popu-
lation of macrophages with DCs-like morphology.
Interestingly, we found that the decrease in circula-
ting myeloid DCs was highest in patients with sys-
temic JIA. The percentage of CD1c+/CD19– cells was
almost three times lower in patients with sJIA then
in other subtypes of juvenile idiopathic arthritis.
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